Women Receive Greater Benefit from Warfarin Therapy in AF

Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Wednesday, February 1, 2006
Follow Pharmacy_Times:

Results of previous studies regarding gender differences and the risk of thromboembolism (TE) in the setting of atrial fibrillation (AF) have been conflicting. A recent study by Fang et al, published in Circulation, however, suggests that women may have a greater risk of TE than men. The investigators conducted a study of over 13,000 patients with AF and recorded data on patients' clinical characteristics and occurrences of hospitalizations for ischemic stroke, hemorrhagic events, and peripheral embolism. An extensive analysis of the data suggested that the rate of TE in women was twice as high in those not taking warfarin. Warfarin use was associated with significantly lower event rates in both sexes. Annual rates of major hemorrhage were similar for men and women. The authors concluded that women are at higher risk for AF-related events off warfarin and that female sex should be considered as an independent risk factor for TE in the setting of AF.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Related Articles
No Result Found
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times